In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

Shares of Akebia Therapeutics fell after the company said it has commenced an underwritten public offering. The stock sank 21% to $2.24 in after-hours trading Wednesday. Shares ended the regular ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics (AKBA) ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

Akebia Therapeutics, Inc. has announced the commencement of an underwritten public offering of its common stock, with all shares being offered by the company itself. Akebia plans to give ...